510(k) Report

PMA · Approved

Approved

THERAKOS® CELLEX® Photopheresis System (CELLEX), THERAKOS® CELLEX® Photopheresis Procedural Kit (CLXUSA and CLXECP), THE

P860003/S112PMAApproved Nov 21, 2025242-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Therakos Development Limited · LNR System, Photopheresis, Extracorporeal

Approved on Nov 21, 2025 through premarket approval, which rests on the device’s own clinical evidence after a 242-day review.

Decided
Nov 21, 2025
Review
242 days
Class
Class III
Product code
LNR
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

FIG. 1 — Lineage of P860003/S112Source: FDA PMA database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LNR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All LNR devices

LNR System, Photopheresis, Extracorporeal: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · LNR

3in 2025

2008: 32009: 42010: 12011: 72012: 52013: 72014: 22015: 52016: 52017: 82018: 42019: 22020: 12021: 22022: 32023: 32025: 3
2007high 8 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LNR

Too few LNR 510(k)s in any year since 2007 to give a median.

Recalls per year · LNR

2in 2021

2010: 22011: 32021: 2
2007high 3 (2011) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LNR

145in 2025

2007: 152008: 82009: 122010: 362011: 942012: 1202013: 2222014: 3772015: 3192016: 3182017: 2612018: 1832019: 1612020: 1412021: 1142022: 972023: 832024: 1512025: 145
2007high 377 (2014) · low 8 (2008)2025

MAUDE reports naming product code LNR, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—015
20083—08
20094—012
20101—236
20117—394
20125—0120
20137—0222
20142—0377
20155—0319
20165—0318
20178—0261
20184—0183
20192—0161
20201—0141
20212—2114
20223—097
20233—083
20240—0151
20253—0145
20260—0—
Cite this page

510(k) Report. “P860003/S112: THERAKOS® CELLEX® Photopheresis System (CELLEX), THERAKOS® CELLEX® Photopheresis Procedural Kit (CLXUSA and CLXECP), THE.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P860003/S112

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026